We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gyg Plc | LSE:GYG | London | Ordinary Share | GB00BZ4FM652 | ORD GBP0.002 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 30.00 | 25.00 | 45.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
11/10/2007 18:38 | Back to 510p? | grigor | |
11/10/2007 15:26 | LOL wad collector! Sorry Robbie, this that was a very bad call methinks. | rivaldo | |
10/10/2007 21:20 | Thanks myl, yep Wad that's cheered me up, shorting GYG blooming cheek. Regards, Maddox | maddox | |
10/10/2007 14:31 | Naked traders get their extremities singed. | wad collector | |
09/10/2007 21:41 | Maddox Naked Trader shorting as follows Stock Epic short Stake Target Stop Gyrus GYG 403 10 350 420 He is shorting on the bases f the dollar as well as the fundamentals dispite the director's recently buys. I hope the above helps | 1318myl | |
09/10/2007 13:26 | Thanks Rivaldo, Yep, the current growth will be masked only if the Dollar continues to decline. On the otherhand I am waiting for the growth rate to crank up from low double digit growth to high teens growth. The base of generators that they now have established in the market must start to be reflected in a ramp-up the disposable hand-set throughput. It is a conservative market that Gyrus is selling to but it has to happen sometime. Regards, Maddox | maddox | |
09/10/2007 10:36 | Nice :o)) "Numis has....a buy and 562p target for Gyrus Group" | rivaldo | |
09/10/2007 10:13 | Maddox, from memory it was mainly to do with the US dollar for obvious reasons, but that's only a short-term thing and will soon be dismissed if the company continues to perform - particularly with such US interest in the stock. | rivaldo | |
08/10/2007 11:45 | 1318myl, What is Naked Trader's rationale? Is is purely technical analysis or are there other reasons? Regards, Maddox | maddox | |
07/10/2007 18:50 | Thx sruk77 - excellent news! | rivaldo | |
07/10/2007 13:39 | Gyrus is not for the squeamish. The company makes medical devices and is particularly successful in selling products that help surgeons with bladder and uterine operations. The business was formed in 1989 by two brothers, one a doctor and the other an electronics enthusiast. Eighteen years on, the brothers have bowed out and Gyrus is valued at almost £600m on the stock market. Sales of more than £220m are forecast for 2007 and the company earns 85% of this in America, the world's largest healthcare market. Gyrus reached its present size under Brian Steer, who was executive chairman from 1996 until June. He has now stepped away from the day-to-day running of the business and taken on a non-executive role. Roy Davis, formerly chief operating officer, has become chief executive and both he and Steer are well regarded in the medical industry and in the City. The company has some world-leading technology. It focuses on enabling surgeons to see what they are doing better in keyhole surgery and helping them to treat patients more effectively by using other specialist devices. Recent growth has been impressive and sales of some products increased by more than 50% last year. The company also wants to make its mark in ear, nose and throat work and general surgery. It is already making significant inroads in these areas and there is plenty of potential as the general surgery market generates sales of about $3bn a year worldwide. MAIL ON SUNDAY also has it as a buy at 397.75p | sruk77 | |
07/10/2007 10:38 | Sorry 1318myl, I s'pose we share the same taste in quality ISA stocks! NT has got this wrong imo. Plenty of institutional and director buying, and there'll always be takeover speculation in the background - not much downside and plenty of upside back to 500p. | rivaldo | |
05/10/2007 21:02 | Rivaldo, I see your name everywhere, vlk, wtm,gyg....lol looking at the notes, it seams everybody is buying with the exception of the naked trader, he is shorting gyg......why do he think gyg is a short rather than along. he brought before........hmmmmm | 1318myl | |
04/10/2007 10:03 | AXA are buying too - they've increased by 836,000 shares: "The Company was informed on 3 October 2007 that, as of 2 October 2007, AXA S.A. held an interest in 11,858,223 ordinary shares of 1p each in the Company, representing approximately 8.01% of the voting rights over the Company's issued share capital." | rivaldo | |
24/9/2007 19:01 | Standard Life have been buying as well as the directors - they're up from 8.6m shares and have bought another 550k or so: "The Company was informed on 24 September 2007 that, as of 21 September 2007, Standard Life Investments Ltd held an interest in 9,151,880 ordinary shares of 1p each in the Company, representing approximately 6.180% of the voting rights over the Company's issued share capital." | rivaldo | |
24/9/2007 12:50 | wad, Good to see the Directors buying, its a good old fashion way of signalling to the market that the Directors feel that their Company's shares are undervalued. I'd like to see more of other Company's Directors put their hand in their own pocket.... rather than ours. Regards, Maddox | maddox | |
19/9/2007 21:09 | Well ,the directors who bought at 386 certainly won't be unhappy with their 8% rise in a couple of days. | wad collector | |
19/9/2007 18:06 | For what this is worth: | das9 | |
18/9/2007 19:06 | One day we may even get a dividend. | wad collector | |
18/9/2007 08:59 | The dollar may start to improve as interest rates outside America may have peaked | grigor | |
18/9/2007 08:05 | Nice summary: "Gyrus Group Our view: Buy Current price: 398p (-35p) Gyrus is a rare beast, a UK medical technology group that has actually managed to deliver on its promises and given shareholders decent returns more than trebling in value over the past five years until the summer sell-off knocked 25 per cent off its value. The weak dollar contributed to yesterday's slightly disappointing 2 per cent growth in first-half revenue to £109.1m, although at constant currency rates the underlying growth was closer to 11 per cent. On the same basis, underlying operating profit was up 13 per cent to £17.5m while basic earnings per share rose by 40 per cent to 3.5p. However, the company's business is heavily weighted to the second half of the year. Gyrus is a pioneer of keyhole surgery technology. Its main business is in urology, gynaecology and ear, nose and throat procedures but there is scope for the company to move into more general medical procedures. Revenues from general surgery were up by 120 per cent in the first half. The company does almost 80 per cent of its business in the US and while the dollar may be having a translational impact at the moment, the underlying operations look to be in decent shape. Post restructuring, margins remain strong at over 16 per cent and directors clearly see yesterday's sell off as a good chance to pick the stock up at historically low levels with the shares trading on under 16 times forecast 2008 earnings, a decent price for strong potential growth." | rivaldo | |
17/9/2007 19:01 | Along with the director buying it's interesting to see the pound going below $2....which will of course benefit GYG greatly. The results looked fine to me - and excellent overall on a constant currency basis. I'd guess that the price will continue to recover from here gi8ven that the numbers only looked disappointing on translation, and if that factor continues to improve GYG could be back at 450p in no time. | rivaldo | |
17/9/2007 17:34 | Interesting to see the Director buys .Presumably that announcement has helped stabilise this afternoon.Ah well , we knew it would be a long haul. | wad collector | |
17/9/2007 10:52 | Wad, Not impressed by these results. I was expecting the dollar effect but the underlying growth is less than I expected. The share price fall also leads me to believe that they have not done anything to lower expectations ahead of these figures. With the Analysts giving a rosey picture, as Rivaldo has posted above, this disappointed reaction was a given. It doesn't pay to undermine the Analyst's confidence in the management team. Regards, Maddox | maddox |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions